NO992936L - Fremgangsmåte for å behandle nyresvikt - Google Patents

Fremgangsmåte for å behandle nyresvikt

Info

Publication number
NO992936L
NO992936L NO992936A NO992936A NO992936L NO 992936 L NO992936 L NO 992936L NO 992936 A NO992936 A NO 992936A NO 992936 A NO992936 A NO 992936A NO 992936 L NO992936 L NO 992936L
Authority
NO
Norway
Prior art keywords
patient
ferric
procedure
accordance
kidney failure
Prior art date
Application number
NO992936A
Other languages
English (en)
Other versions
NO992936D0 (no
NO327148B1 (no
Inventor
Chen Hsing Hsu
Original Assignee
Chen Hsing Hsu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26708838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO992936(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chen Hsing Hsu filed Critical Chen Hsing Hsu
Publication of NO992936D0 publication Critical patent/NO992936D0/no
Publication of NO992936L publication Critical patent/NO992936L/no
Publication of NO327148B1 publication Critical patent/NO327148B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Liquid Crystal Substances (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
NO19992936A 1996-12-16 1999-06-16 Anvendelse av ferrisitrat, ferriaccetat og kombinasjoner av disse for fremstilling av medikamenter NO327148B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3274596P 1996-12-16 1996-12-16
US08/794,328 US5753706A (en) 1996-12-16 1997-02-03 Methods for treating renal failure
PCT/US1997/020977 WO1998026776A1 (en) 1996-12-16 1997-11-14 Method for treating renal failure

Publications (3)

Publication Number Publication Date
NO992936D0 NO992936D0 (no) 1999-06-16
NO992936L true NO992936L (no) 1999-08-13
NO327148B1 NO327148B1 (no) 2009-05-04

Family

ID=26708838

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19992936A NO327148B1 (no) 1996-12-16 1999-06-16 Anvendelse av ferrisitrat, ferriaccetat og kombinasjoner av disse for fremstilling av medikamenter

Country Status (12)

Country Link
US (1) US5753706A (no)
EP (1) EP0959878B1 (no)
JP (2) JP4173553B2 (no)
KR (1) KR100464504B1 (no)
AT (1) ATE400264T1 (no)
AU (1) AU723091B2 (no)
CA (1) CA2272711C (no)
DE (1) DE69738824D1 (no)
ES (1) ES2310417T3 (no)
IL (1) IL130041A (no)
NO (1) NO327148B1 (no)
WO (1) WO1998026776A1 (no)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9750715B2 (en) 2006-01-30 2017-09-05 Panion & Biotech Inc. Method of reversing, preventing, delaying or stabilizing soft tissue calcification
US9757416B2 (en) 2003-02-19 2017-09-12 Panion & Bf Biotech Inc. Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
US20040020852A1 (en) * 2000-06-15 2004-02-05 Lars-Fride Olsson Method and apparatus for calcium profiling in dialysis
US6887897B2 (en) 2001-07-31 2005-05-03 Mission Pharmacal Company Calcium glutarate supplement and phosphorus binder
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8592421B2 (en) 2003-08-04 2013-11-26 Valery Khazhmuratovich Zhilov Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
US6903235B2 (en) * 2003-10-08 2005-06-07 Panion & Bf Biotech Inc. Pharmaceutical-grade ferric citrate
US20060046964A1 (en) * 2004-09-02 2006-03-02 Andre Morneau Pharmaceutical formulations and methods
EP1830832A1 (en) * 2004-12-30 2007-09-12 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
CA2619591C (en) * 2005-08-18 2020-03-24 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
US8986669B2 (en) * 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
EP1945196A2 (en) * 2005-11-08 2008-07-23 Genzyme Corporation Magnesium-containing polymers for hyperphosphatemia
US7985429B2 (en) 2006-03-03 2011-07-26 C. B. Fleet Company, Inc. Flavored colonic cleansing system
EP2043627A2 (en) * 2006-07-05 2009-04-08 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
EP2194977A1 (en) * 2007-08-31 2010-06-16 C.B. Fleet Company Incorporated Method of preventing nephrocalcinosis
EP2334292B1 (en) * 2008-10-17 2019-05-08 Fresenius Medical Care Holdings, Inc. Method of determining a phosphorus binder dosage for a dialysis patient
CN103800310A (zh) * 2008-10-27 2014-05-21 思佰益药业股份有限公司 以5-氨基乙酰丙酸或其衍生物、或它们的盐作为有效成分的成人病的预防、改善剂
WO2011011541A1 (en) * 2009-07-21 2011-01-27 Henry Trong Le Ferric citrate dosage forms
JP5894533B2 (ja) * 2009-10-01 2016-03-30 フレゼニウス メディカル ケア ホールディングス インコーポレイテッド リン−タンパク質比の計算方法
JP5167389B2 (ja) * 2010-07-07 2013-03-21 日本たばこ産業株式会社 クエン酸第二鉄を含む錠剤
JP2012162522A (ja) * 2011-01-18 2012-08-30 Japan Tobacco Inc β酸化水酸化鉄を実質的に含まないクエン酸第二鉄
US20130345303A1 (en) * 2012-06-21 2013-12-26 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of chronic kidney disease patients
EP3003327B1 (en) 2013-06-05 2017-08-09 Tricida Inc. Proton-binding polymers for oral administration
WO2015110968A1 (en) 2014-01-23 2015-07-30 Lupin Limited Pharmaceutical grade ferric citrate and method for its production
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
RS61409B1 (sr) 2014-12-10 2021-03-31 Tricida Inc Polimeri koji vezuju protone za oralnu primenu opis
JP6206420B2 (ja) * 2015-01-13 2017-10-04 テクノサイエンス株式会社 クエン酸第二鉄を高濃度で含有するゲル状組成物の製造方法
JP2018526349A (ja) 2015-08-05 2018-09-13 ルピン・リミテッド 医薬品グレードのクエン酸第二鉄の調製のためのプロセス
CN109414453B (zh) 2016-05-06 2023-02-17 特里赛达公司 用于治疗酸碱失衡的组合物
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
CA3080651A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1131360B (de) * 1957-11-26 1962-06-14 Vitarine Company Inc Verfahren zum Stabilisieren von waessrigen Loesungen, die neben Vitamin B noch Vitamin B und Vitamin C enthalten
DE3228231A1 (de) * 1982-07-28 1984-02-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München Arzneimittel, calciummischsalze von polymeren, anionischen carbonsaeuren und/oder schwefelsaeureestern, verfahren zu ihrer herstellung und ihre verwendung
GB2212396A (en) * 1987-12-18 1989-07-26 Procter & Gamble Dietary supplement comprising calcium and delayed release coated iron
US4970079A (en) * 1989-06-05 1990-11-13 Purdue Research Foundation Method and composition of oxy-iron compounds for treatment of hyperphosphatemia
DE4239442C2 (de) * 1992-11-24 2001-09-13 Sebo Gmbh Verwendung eines mit polynuklearen Metalloxidhydroxiden modifizierten Adsorptionsmaterials zur selektiven Elimination von anorganischem Phosphat aus proteinhaltigen Flüssigkeiten
JPH08198760A (ja) * 1995-01-20 1996-08-06 Japan Organo Co Ltd 経口用リン酸イオン吸着剤
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757416B2 (en) 2003-02-19 2017-09-12 Panion & Bf Biotech Inc. Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
US9750715B2 (en) 2006-01-30 2017-09-05 Panion & Biotech Inc. Method of reversing, preventing, delaying or stabilizing soft tissue calcification

Also Published As

Publication number Publication date
KR100464504B1 (ko) 2004-12-31
KR20000069414A (ko) 2000-11-25
NO992936D0 (no) 1999-06-16
EP0959878A4 (en) 2002-03-27
JP2007217429A (ja) 2007-08-30
IL130041A0 (en) 2000-02-29
US5753706A (en) 1998-05-19
JP4173553B2 (ja) 2008-10-29
CA2272711C (en) 2008-04-29
CA2272711A1 (en) 1998-06-25
DE69738824D1 (de) 2008-08-21
IL130041A (en) 2005-08-31
ES2310417T3 (es) 2009-01-01
WO1998026776A1 (en) 1998-06-25
ATE400264T1 (de) 2008-07-15
JP2001506262A (ja) 2001-05-15
AU723091B2 (en) 2000-08-17
EP0959878B1 (en) 2008-07-09
AU5441998A (en) 1998-07-15
NO327148B1 (no) 2009-05-04
EP0959878A1 (en) 1999-12-01

Similar Documents

Publication Publication Date Title
NO992936L (no) Fremgangsmåte for å behandle nyresvikt
Lockwood et al. Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis.
JPS6248623A (ja) 胃腸疾患の治療のための医薬組成物
CA2238040A1 (en) Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders and other applications
CA2150184A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel diseases
Zinberg et al. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis.
Perkins Apnea with intramuscular colistin therapy
WO2003011225A3 (en) Calcium glutarate supplement and phosphorus binder
CA2344910A1 (en) Method for treating renal disease, and pharmaceutical composition for treating renal disease
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
Tori et al. Urolithiasis in children with spinal cord injury
Kampmann et al. Ampicillin and propylthiouracil pharmacokinetics in intestinal bypass patients followed up to a year after operation
EP0219912B1 (en) The use of nitrofurantoin for the treatment and prophylaxis of gastrointestinal disorders
Hautmann et al. Calcium oxalate stone disease: effects and side effects of cellulose phosphate and succinate in long-term treatment of absorptive hypercalciuria or hyperoxaluria
Mizutani et al. Rectal ulcer with massive haemorrhage due to activated charcoal treatment in oral organophosphate poisoning
Lacher et al. Sweating treatment for chronic renal failure
Lichtenberg et al. Tolbutamide-associated hyponatremia
RU2150277C1 (ru) Лечение констипации методом кишечного лаважа в.а.маткевича
Gasbarrini et al. Pirenzepine in the treatment of benign gastroduodenal diseases. A double-blind controlled clinical trial
Gibb et al. Survival in Whipple's disease
RU2182003C2 (ru) Способ лечения нарушения энтерогепатической циркуляции желчи у больных с наружным дренированием желчных путей
Rizhik et al. Possibilities of computerized tomography method in determination of choledoch permeability
Abboud Nephrolithiasis in Patients with Gastrointestinal Disorders
JPS61106520A (ja) 免疫抑制物質除去剤
Pinto et al. Five-Year Treatment in Hyperoxaluric Stone Formers

Legal Events

Date Code Title Description
MK1K Patent expired